Viemed Healthcare, Inc. (VMD) Seasonal Returns Chart - Yahoo Finance
The article displays the seasonal returns chart for Viemed Healthcare, Inc. (VMD) on Yahoo Finance, showing its average monthly price return from 2019 to 2026. As of November 13, the stock closed at $9.17 with a slight gain.
Freedom Broker maintains Viemed Healthcare at Hold, lowers price target to $10 from $11
Freedom Broker has reiterated its "Hold" rating on Viemed Healthcare and reduced its price target for the company from $11 to $10. This new price target suggests a potential upside of 9.5% from the closing price on November 6th. Investors can find more detailed analyst ratings and price target data for Viemed Healthcare on the Forecasts tab and within the dedicated News Flow section.
Viemed Healthcare Q3 2026 Earnings Call Transcript
Viemed Healthcare reported strong Q3 2026 results with record revenue of $80.7 million, up 12.2% year-over-year, and a 32% increase in net income. The company is expanding its maternal health services into two new states per quarter and saw significant growth in PAP therapy patients, up 37.5% year-over-year. Financial guidance for the full year was updated, with revenue now projected between $316 million and $320 million, and adjusted EBITDA narrowed to $64 million to $66 million, reflecting confidence in continued organic growth and operational efficiency.
Viemed Q3 2026 Earnings: Revenue Rises 12.2% as Profitability Rebounds
Viemed Healthcare reported a strong Q3 2026 with net revenue up 12.2% year-over-year to $80.7 million and diluted EPS increasing to $0.11. Net income surged by 32.0% to $4.6 million, largely due to gross profit expansion and reduced interest expenses, marking a significant sequential rebound in profitability. The company also raised the lower end of its full-year revenue guidance and decreased capital expenditure expectations, signaling improved operational efficiency and a shift towards less capital-intensive services.
Viemed Healthcare, Inc. (VMD) Misses Q3 EPS by 2c; updates guidance
Viemed Healthcare, Inc. (VMD) reported its Q3 EPS of $0.11, which missed analyst estimates by $0.02, and revenue of $80.7 million, slightly below the consensus. The company also updated its FY2026 revenue guidance to $316-320 million, aligning with analyst expectations.
Viemed Healthcare, Inc. Set to Report Q3 Results Before U.S. Market Opens
Viemed Healthcare, Inc. (VMD) is scheduled to release its third-quarter results before the U.S. market opens on Thursday, November 5. Analysts anticipate earnings per share of $0.12 and a revenue of $80.78 million, representing a 12.3% increase from the previous year's quarter. These figures are based on pre-release estimates.
VieMed Healthcare (NASDAQ:VMD) Posts Mixed Q3 Results as Revenue Meets but EPS Misses
VieMed Healthcare (NASDAQ:VMD) reported mixed third-quarter 2026 results, with revenue largely meeting analyst expectations but earnings per share falling short. The company posted net revenue of $80.7 million, up 12.2% year-over-year, while reported EPS came in at $0.11, below the $0.1279 consensus estimate. Management refined its full-year guidance, raising the low end of its revenue range and reducing planned capital spending, leading to a flat after-market reaction from investors.
Form 8K Viemed Healthcare Inc For: 4 November By Investing.com
This article announces that Viemed Healthcare Inc. filed a Form 8K on November 4th. The filing is an important regulatory disclosure for investors interested in the company (VMD). The article itself is brief, primarily serving as an alert for the SEC filing.
Viemed Healthcare Announces Third Quarter 2026 Financial Results
Viemed Healthcare, Inc. (NASDAQ:VMD) announced record net revenue of $80.7 million for the third quarter of 2026, marking a 12.2% increase year-over-year, alongside a significant 67.8% sequential rise in net income to $4.6 million. The company also updated its full-year 2026 guidance, raising the low end of its revenue outlook to a range of $316 million to $320 million and narrowing its Adjusted EBITDA guidance to $64 million to $66 million, reflecting continued growth and improved operating leverage. CEO Casey Hoyt highlighted the strength of Viemed's diversified platform across respiratory, sleep, and women’s health businesses, attributing improved profitability to strategic investments and increased efficiencies.
Form 8K Viemed Healthcare Inc For: 4 November By Investing.com
This article from Investing.com announces the filing of a Form 8K by Viemed Healthcare Inc. for November 4th. The content primarily consists of the headline repeated several times, indicating a corporate filing event. No specific details about the contents of the 8K are provided within the article body.
Revenue rises 12.2% at Viemed Healthcare (VMD), but its 2026 adjusted EBITDA forecast narrows.
Viemed Healthcare, Inc. (VMD) reported strong third-quarter 2026 results with revenue up 12.2% year-over-year to $80.7 million and net income attributable to Viemed increasing 32.0% to $4.6 million. The company narrowed its full-year 2026 Adjusted EBITDA guidance to $64 million to $66 million, from a previous range of $64 million to $68 million, while raising the low end of its revenue guidance. Viemed also authorized a new share repurchase program for up to 5% of its shares outstanding.
Revenue rises 12.2% at Viemed Healthcare (VMD), with quarterly profit growing faster.
Viemed Healthcare, Inc. (VMD) reported a 12.2% increase in third-quarter 2026 revenue, reaching $80.673 million, and a 32% rise in net income attributable to Viemed, totaling $4.638 million. This growth was fueled by increased demand across sleep therapy, complex respiratory care, and women’s health products and services. For the nine months ended September 30, 2026, operating cash flow was $35.460 million, and the company repurchased 795,802 common shares for $7.5 million.
Viemed Healthcare Announces Third Quarter 2026 Financial Results
Viemed Healthcare, Inc. (NASDAQ:VMD) reported record financial results for the third quarter of 2026, with net revenue reaching $80.7 million, a 12.2% increase year-over-year, and net income attributable to Viemed increasing by 32.0% to $4.6 million. The company also updated its full-year 2026 guidance, raising the lower end of its revenue forecast and narrowing its Adjusted EBITDA range, reflecting continued growth across its diversified platform. Viemed’s CEO, Casey Hoyt, highlighted the double-digit revenue growth and significant improvement in profitability, attributing it to a diversified platform and enhanced operating leverage.
Trading Systems Reacting to (VMD) Volatility
Viemed Healthcare Inc. (NYSE: VMD) is experiencing weak near-term sentiment, challenging its long-term strength with support being tested. AI models have generated three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with an exceptional 45.7:1 risk-reward setup targeting a 14.8% gain against a 0.3% risk. Multi-timeframe analysis reveals weak near-term, neutral mid-term, and strong long-term signals for the stock.
Viemed Healthcare, Inc. (VMD) Seasonal returns chart
This article from Yahoo Finance presents a seasonal returns chart for Viemed Healthcare, Inc. (VMD). It shows the average monthly price return for the company between 2019 and 2026. The article also includes current stock information for VMD and various market indices.
Viemed Healthcare (VMD) Set to Post Quarterly Earnings on Wednesday
Viemed Healthcare (NASDAQ:VMD) is slated to report its Q3 2026 earnings after market close on November 4th, with analysts forecasting $0.12 EPS and $80.78 million in revenue. The company missed its Q2 earnings estimates but slightly beat revenue expectations. Analysts currently have a consensus "Hold" rating on the stock with a $14.00 price target, though one firm recently initiated coverage with an "Outperform" rating.
Viemed Healthcare, Inc. Estimates – FWB:VIJ
The article provides an overview of Viemed Healthcare, Inc. (FWB:VIJ) financial data and analyst estimates available on TradingView. It highlights sections for exploring reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics. Users can compare actual results with average, high, and low estimates and visualize trends over time.
Viemed Healthcare, Inc. Estimates – SWB:VIJ
This article provides an overview of Viemed Healthcare, Inc. (VIJ) listed on the Stuttgart Stock Exchange, focusing on its financial actuals and analyst estimates. It allows users to explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics. The platform emphasizes that this information is not investment advice and encourages users to conduct their own research.
Viemed Healthcare Maps Growth in Home Respiratory Care, Sleep and Maternal Health
Viemed Healthcare outlined its strategy for expanding home-based respiratory care, diversifying revenue, and maintaining organic growth, serving 200,000 patients across the U.S. The company's core business is complex respiratory care, with noninvasive ventilation having less than 10% market penetration, and it is diversifying into sleep apnea products, oxygen, and maternal health. Viemed projects 2026 revenue of $315 million to $320 million and adjusted EBITDA in the mid-$60 million range, anticipating benefits from inflation-related reimbursement increases and continued share repurchases.
Viemed Healthcare Announces Third Quarter 2026 Earnings Conference Call Details
Viemed Healthcare, Inc. (NASDAQ:VMD) has announced that it will host its Third Quarter 2026 Earnings Conference Call on Thursday, November 5, 2026, at 11:00 a.m. EST. Interested parties can join the call via phone or live audio webcast. A replay will be available on the company's Investor Relations website following the call.
Viemed Healthcare Announces Third Quarter 2026 Earnings Conference Call Details
Viemed Healthcare, Inc. will host its Third Quarter 2026 Earnings Conference Call on Thursday, November 5, 2026, at 11:00 a.m. EST. Interested parties can join via a toll-free number, an international number, or a live audio webcast. A replay will be available on the company's investor relations website after the call.
Viemed Healthcare Announces Third Quarter 2026 Earnings Conference Call Details
Viemed Healthcare, Inc. announced details for its Third Quarter 2026 Earnings Conference Call, scheduled for Thursday, November 5, 2026, at 11:00 a.m. EST. Interested parties can join via a toll-free number or international dial-in, and a live audio webcast will also be available. A replay will be posted on the company's Investor Relations website following the call.
Viemed Healthcare Announces Third Quarter 2026 Earnings Conference Call Details
Viemed Healthcare, Inc. announced details for its Third Quarter 2026 Earnings Conference Call, scheduled for Thursday, November 5, 2026, at 11:00 a.m. EST. Interested parties can participate via a dial-in number or a live audio webcast, with a replay available afterward on the company's website. Viemed specializes in technology-enabled, home-based healthcare solutions, including respiratory, chronic care, and women’s health products and services.
Viemed Healthcare Q3 2026 Earnings Date and Estimates
Viemed Healthcare (NASDAQ:VMD) is projected to release its Q3 2026 earnings on Wednesday, November 4, 2026, after market close, with a conference call scheduled for November 5, 2026, at 11:00 AM ET. Analysts anticipate earnings of $0.12 per share on $80.78 million in revenue, representing a 33.3% increase in EPS and 12.3% revenue growth year-over-year. The company previously reported Q2 2026 earnings of $0.07 per share, missing the consensus estimate.
VMD: Home-based care and portfolio expansion support growth and 2026 guidance of $317M revenue midpoint
Viemed Healthcare, Inc. (VMD) is projected to achieve a 2026 revenue midpoint of $317 million, supported by its home-based respiratory care services and expanded portfolio in sleep and maternal health. The company anticipates an adjusted EBITDA midpoint of $66 million with no net debt and ongoing stock buybacks. This information is based on an audio transcript from the LD Micro 20th Annual Main Event Conference.
Viemed presents at LD Micro while Viemed Healthcare stock costs EUR 8.55
Viemed Healthcare presented at the LD Micro Main Event on October 20, 2026, where its stock was trading at EUR 8.55. The company's Q2 2026 revenue reached USD 78.10 million, with full-year revenue guidance set to begin at USD 314.00 million. Despite a lowered adjusted EBITDA guidance due to faster expansion in newer service lines, the stock's valuation remains data-dependent as the company anticipates its Q3 2026 results on November 4, 2026.
Viemed schedules October 20 presentation. Barrington target for Viemed stock is USD 14.00
Viemed Healthcare is set to present at the LD Micro Main Event on October 20, 2026, where CEO Casey Hoyt will represent the company. This presentation follows the announcement of Q2 results, which reported revenue of USD 78.10 million and diluted EPS of USD 0.07. Barrington Research has set an Outperform rating and a USD 14.00 price target for Viemed stock, with the next earnings call estimated for November 4, 2026.
Viemed Healthcare schedules October 20 event for Viemed Healthcare stock
Viemed Healthcare (VMD) is scheduled to present on October 20, 2026, after releasing Q2 2026 earnings that showed revenue of USD 78.10 million, slightly above consensus. The company's revenue mix is shifting away from ventilator rentals towards equipment sales and services, leading to a revised full-year adjusted EBITDA guidance of USD 64.00 million to USD 68.00 million. Investors will be looking for clarity on margin execution during the upcoming presentation.
Viemed Healthcare Currently Up Nine Consecutive Days, on Pace for Longest Winning Streak Since July 2022 -- Data Talk
Viemed Healthcare (VMD) stock has been on a nine-day winning streak, marking its longest continuous gain since July 2022. This performance indicates a significant positive momentum for the company's shares. Investors are closely watching to see if this trend will continue and what factors might be driving this consistent upward movement.
Understanding the Setup: (VMD) and Scalable Risk
This article analyzes Viemed Healthcare Inc. (NYSE: VMD), highlighting strong sentiment across all horizons and an exceptional 46.0:1 risk-reward setup. It outlines three AI-generated trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, complete with entry zones, targets, and stop losses. The analysis also provides multi-timeframe signal strengths, support, and resistance levels for near-term, mid-term, and long-term horizons.
Viemed sets October 20 event while Viemed Healthcare stock trades below EUR 8.38
Viemed Healthcare (VMD) is trading below its prior close at EUR 8.30 on October 8, 2026, despite reporting a 24% increase in Q2 2026 revenue to USD 78.10 million. The company announced it would present at the LD Micro Main Event on October 20, 2026, where CEO Casey Hoyt and management will discuss the company's performance and outlook, including raised full-year revenue guidance. The stock's current price reflects a slight dip from its previous close, with the company facing a margin trade-off as adjusted EBITDA decreased compared to the prior year.
Do Options Traders Know Something About Viemed Stock We Don't?
The article discusses the high implied volatility in Viemed Healthcare (VMD) stock options, particularly the Nov. 20, 2026 $5.00 Call. This suggests options traders are anticipating a significant price movement for Viemed. Despite this, analysts currently rate Viemed as a Zacks Rank #3 (Hold), with recent earnings estimates showing a slight decrease.
Do Options Traders Know Something About Viemed Stock We Don't?
Options traders are showing high implied volatility for Viemed Healthcare, Inc. (VMD) stock, suggesting expectations for a significant price movement. This comes as analysts currently rate Viemed as a Zacks Rank #3 (Hold) and have slightly lowered earnings estimates for the upcoming quarter. The increased options activity could indicate a potential trading opportunity or a strategy by seasoned traders to sell premium, betting the stock won't move as much as implied.
Do Options Traders Know Something About Viemed Stock We Don't?
Options traders are showing significant interest in Viemed Healthcare, Inc. (VMD), with a specific call option exhibiting high implied volatility, suggesting expectations for a substantial price movement. Despite this, analysts currently rate Viemed as a Zacks Rank #3 (Hold) in the Medical - Products industry. This divergence could indicate a potential trading opportunity for seasoned traders who might sell premiums to capitalize on time decay.
Viemed Healthcare, Inc. to Present at the 20th Annual LD Micro Main Event
Viemed Healthcare, Inc. (NASDAQ: VMD) announced its participation in the 20th Annual LD Micro Main Event, scheduled for October 19-21, 2026, in Los Angeles. CEO Casey Hoyt and other management will present on Tuesday, October 20, 2026, at 12:30 PM PT. The event will feature over 100 public companies presenting to investors.
Viemed Healthcare, Inc. to Present at the 20th Annual LD Micro Main Event
Viemed Healthcare, Inc. announced its participation in the 20th Annual LD Micro Main Event, scheduled for October 19-21, 2026, in Los Angeles. The company, a provider of home medical equipment and post-acute healthcare services, will present on Tuesday, October 20, 2026, at 12:30 PM PT. CEO Casey Hoyt and other management members will represent Viemed at this event, which features presentations from over 100 public companies to investors.
More than 100 companies are taking part in a Los Angeles investor event; Viemed is scheduled to present Oct. 20.
Viemed Healthcare (NASDAQ: VMD) is set to present at the 20th Annual LD Micro Main Event on October 20, 2026, in Los Angeles. CEO Casey Hoyt and other management members will represent the company at the event, which runs from October 19-21, 2026, and features over 100 public companies presenting to investors. Viemed Healthcare specializes in home medical equipment and post-acute healthcare services, focusing on respiratory, chronic care, and women's health.
Viemed Healthcare to present at LD Micro Main Event in October 2026
Viemed Healthcare, a U.S. provider of home medical equipment and post-acute healthcare services, announced it will present at the 20th Annual LD Micro Main Event on October 20, 2026, in Los Angeles. CEO Casey Hoyt and management will represent the company, highlighting Viemed's focus on respiratory, chronic care, and women's health services delivered at home. The event offers Viemed an opportunity to connect with investors and showcase its technology-enabled care model, with the presentation also available via webcast.
Viemed Healthcare, Inc. to Present at the 20th Annual LD Micro Main Event
Viemed Healthcare, Inc. announced its participation in the 20th Annual LD Micro Main Event, scheduled for October 19-21, 2026, in Los Angeles. The company, a provider of home medical equipment and post-acute healthcare services, will present on Tuesday, October 20, 2026, at 12:30 PM PT. CEO Casey Hoyt and other management members will represent Viemed at the event, which features over 100 public companies presenting to investors.
Viemed Healthcare, Inc. to Present at the 20th Annual LD Micro Main Event
Viemed Healthcare, Inc. announced its participation in the 20th Annual LD Micro Main Event, scheduled for October 19-21, 2026, in Los Angeles, California. The company will present on Tuesday, October 20, 2026, at 12:30 PM PT, with CEO Casey Hoyt and other management members representing Viemed. The event will feature over 100 public companies presenting to investors and offering private meeting opportunities.
(VMD) as a Liquidity Pulse for Institutional Tactics
This article provides an AI-driven analysis of Viemed Healthcare Inc. (NYSE: VMD), focusing on liquidity and institutional trading tactics. It outlines near-term strong sentiment, mid-term neutrality, and long-term positive bias, along with specific trading strategies (Position, Momentum Breakout, Risk Hedging) and multi-timeframe signal analysis. The report highlights elevated downside risk and encourages users to sign in for full access to real-time signals and personalized analysis.
Viemed Healthcare Announces Completion of Share Repurchase Program
Viemed Healthcare, Inc. (NASDAQ:VMD) has announced the completion of its share repurchase program, buying back all 1,976,441 authorized common shares at a total cost of approximately $13.2 million. This move, representing 5% of outstanding shares at the time of authorization, demonstrates the company's confidence in its long-term outlook and commitment to enhancing shareholder value. Viemed plans to continue investing in growth opportunities while returning capital to shareholders, supported by a strong balance sheet and increasing free cash flow.
Viemed Healthcare, Inc. $VMD Shares Newly Bought by Bank of America Corp DE
Bank of America Corp DE recently acquired 158,762 shares of Viemed Healthcare (NASDAQ:VMD) in the second quarter, a stake valued at approximately $1.81 million, now holding 0.42% of the company. Viemed Healthcare's recent quarterly earnings of $0.07 per share missed the consensus estimate, though revenue was in line with expectations. Institutional investors collectively own 74.24% of the company, and analysts currently have a "Hold" rating on the stock with an average price target of $14.00.
Barrington Maintains Viemed Healthcare(VMD.US) With Buy Rating, Maintains Target Price $14
Barrington has reiterated its Buy rating for Viemed Healthcare (VMD.US), maintaining a target price of $14. This indicates a continued positive outlook from the firm regarding the company's stock performance and valuation.
Viemed Healthcare Announces Completion of Share Repurchase Program
Viemed Healthcare, Inc. announced the completion of its share repurchase program, buying back 1,976,441 common shares for approximately $13.2 million at a weighted average price of $6.69 per share. The company's CEO, Casey Hoyt, stated that this reflects confidence in Viemed's long-term outlook and commitment to enhancing shareholder value, supported by a strong balance sheet and increasing free cash flow. Viemed plans to continue investing in growth opportunities and returning capital to shareholders.
Viemed Healthcare shifts to diversified home healthcare, boosting growth and cash flow.
Viemed Healthcare (VMD) is transitioning from a respiratory equipment provider to a diversified home healthcare company, expanding into sleep, resupply, and women's health. This strategic shift is driving strong revenue growth and improving free cash flow, despite some margin pressure. Analysts rate VMD as a Strong Buy due to its growth potential, flexible capital allocation, and a strong margin of safety in its valuation.
Viemed Healthcare Announces Adoption of Automatic Securities Disposition Plan by President Michael Moore
Viemed Healthcare, Inc. announced that its President, Michael Moore, has adopted an automatic securities disposition plan (ASDP) for up to 246,000 common shares. This plan, established in compliance with securities laws and Viemed's policies, allows for pre-arranged stock sales without insider discretion, commencing as early as December 24, 2026, over approximately one year. The shares represent less than 11% of Mr. Moore's beneficially owned common shares.
Viemed Healthcare, Inc. (VMD) President Sets 10b5-1 Plan to Sell Up to 246K Shares
Viemed Healthcare, Inc. (VMD) President Michael Moore has adopted a Rule 10b5-1 plan to sell up to 246,000 shares over approximately one year, ending November 30, 2027. Sales may commence as early as December 24, 2026, and are subject to a minimum floor price. This plan represents less than 11% of Moore's total holdings and is a standard insider selling framework.
An officer owns 5.9% of Viemed Healthcare (VMD); an LLC holding his shares has a sale plan.
Viemed Healthcare officer Michael Moore, through his LLC, Moore Faster LLC, has entered into a Rule 10b5-1 trading plan to sell up to 246,000 common shares. Moore beneficially owns 2,294,018 common shares, representing 5.9% of the company, with sales under the plan scheduled to begin no earlier than December 24, 2026, and end by November 30, 2027. This plan is designed to comply with SEC guidelines for insiders to sell shares without being in possession of material non-public information.
Viemed Healthcare Announces Adoption of Automatic Securities Disposition Plan by President Michael Moore
Viemed Healthcare, Inc. (NASDAQ:VMD) announced that its President, Michael Moore, has adopted an automatic securities disposition plan (ASDP) to sell up to 246,000 common shares over approximately one year, ending November 30, 2027. The plan was established in compliance with U.S. and Canadian securities laws and Viemed's internal policies, at a time when Mr. Moore was not in possession of any material non-public information. These shares represent less than 11% of Mr. Moore's beneficially owned shares, and sales may begin as early as December 24, 2026, subject to a minimum floor price.